PARP7 Inhibitor Crystal Forms for Restoring Interferon Signaling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PARP7 inhibitors face challenges in effectively inhibiting cancer cell growth and restoring interferon signaling, which are crucial for tumor suppression, due to limitations in their crystalline forms and preparation methods.
Innovation Solution
Development of specific crystalline forms of PARP7 inhibitors, characterized by distinct X-ray powder diffraction patterns and thermal analysis profiles, along with their preparation methods, including solvent-based crystallization processes, to enhance therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional PARP7 inhibitors are used, then some tumor growth inhibition is achieved, but therapeutic efficacy is insufficient due to limitations in crystalline forms and preparation methods
Solution Approach 1:
The patent applies parameter changes by developing multiple crystalline forms (Form I, Form II, Form III) of PARP7 inhibitors with distinct X-ray powder diffraction patterns and thermal analysis profiles. Each crystalline form represents a different physical state parameter of the same chemical compound, enabling improved therapeutic efficacy while maintaining manufacturability through solvent-based crystallization processes
Solution Approach 2:
The patent utilizes phase transitions by characterizing and utilizing different crystalline phases of the PARP7 inhibitor. The invention describes specific crystallization processes that induce phase transitions from amorphous or poorly crystalline states to well-defined crystalline forms, thereby enhancing drug stability, solubility, and overall therapeutic performance
2Reliability
If new crystalline forms are developed to improve therapeutic efficacy, then tumor growth inhibition and immune memory induction are enhanced, but the complexity of preparation methods increases
Solution Approach 1:
The patent applies segmentation by dividing the preparation process into distinct stages for different crystalline forms. Each crystalline form has its own optimized preparation protocol using specific solvents and conditions, allowing the complex problem of improving therapeutic efficacy to be broken down into manageable, form-specific preparation methods that can be selected based on the desired outcome
Solution Approach 2:
The patent uses solvent-based crystallization processes as intermediary steps to transform the PARP7 inhibitor into different crystalline forms. The solvents act as mediators that facilitate controlled phase transitions and crystal growth, enabling the production of enhanced therapeutic agents without requiring overly complex preparation equipment or procedures
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The crystalline forms of PARP7 inhibitors demonstrate improved tumor growth inhibition and immune memory induction, effectively suppressing cancer by restoring interferon signaling and enhancing immune system signaling.
Implementation Method 1
PARP7 has been shown to ADP-ribosylate TBK1, preventing TBK1 activation and thereby inhibiting the type I interferon response
Implementation Method 2
which has characteristic peak(s) at 1, 2, 3, 4, or 5 of 2θ values of 14.13°, 15.56°, 17.33°, 18.07°, and 22.30°, each with a 2θ error range of ± 0.2° in an X-ray powder diffraction pattern
Implementation Method 3
X-ray powder diffraction pattern as measured using Cu-K α radiation
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
A crystal form of a compound of formula (I) that serves as a PARP7 inhibitor, a crystal form of a pharmaceutically acceptable salt of the compound of formula (I), and the use thereof in the preparation of a drug for treating related diseases. (FIG. 1)